|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/16 | |
| A61K 9/20 | |||
| A61K 31/506 |
| (11) | Number of the document | 2585048 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11728490.1 |
| Date of filing the European patent application | 2011-06-17 | |
| (97) | Date of publication of the European application | 2013-05-01 |
| (45) | Date of publication and mention of the grant of the patent | 2018-04-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/040972 |
| Date | 2011-06-17 |
| (87) | Number | WO 2011/163090 |
| Date | 2011-12-29 |
| (30) | Number | Date | Country code |
| 357981 P | 2010-06-23 | US |
| (72) |
MCWHERTER, Charles A., US
MARTIN, Robert Louis, US
KARPF, David B., US
ROBERTS, Brian K., US
LORENZ, Douglas Alan, US
KETNER, Rodney James, US
|
| (73) |
CymaBay Therapeutics, Inc.,
3876 Bay Center Place, Hayward, CA 94545,
US
|
| (54) | COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE |
| COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE |